SRZN Surrozen, Inc. stock chart & analysis

Conviction 2HealthcareScan · Tue, Nov 10, 2026

Tweezer top

Surrozen, Inc. (SRZN) closed at $32.74 (+2.31%) on Nov 10, 2026. Its latest daily candle is a tweezer top. Price is above its 50-day and above its 200-day moving average. RSI(14) 63, RS Rating 99, -13.5% from its 52-week high, +44.9% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).

SRZN$32.74+2.31%

ResistanceSupportVol 14Insider sell

Loading chart…

Why SRZN moved

From the StockSetups movers recaps that covered SRZN, newest first. A recap states what was known that day.

Sep 24, 2026Close+108.2%
No researched catalyst headline is on file for SRZN for today's session. However, the technical and short-interest data tell a compelling story.
Top Stock Movers Sept 24, 2026: APUS, SRZN, GLND →
Sep 24, 2026Premarket+78.8%
No specific catalyst headline is on file ahead of the open. With no confirmed news, the move appears to be technically and squeeze-driven. Surrozen carries a squeeze score of 81/100 — one of the most compelling short-squeeze setups in this morning's scan.
Premarket Movers Sept 24, 2026: APUS, SRZN, PFSA →

Surrozen, Inc.Biological Products, (No Diagnostic Substances)www.surrozen.com ↗

Price32.74

Change+2.31%

Gap+2.47%

Rel volume0.63×

Avg volume324.08K

Avg $ vol8.72M

SMA 2027.95

SMA 5025.35

SMA 20025.49

Price vs 50+29.15%

Price vs 200+28.43%

MA stackmixed

50/200 cross—

Supertrendup · 25.37

RSI (14)63

MACD hist0.36

MACD cross—

Stoch %K / %D92 / 85

ADX (14)35

+DI / −DI33 / 14

RSI divergence—

MACD divergence—

ATR %7.48%

ADR %7.57%

52w high37.83

52w low11.66

From 52w high-13.45%

Above 52w low+180.79%

New 52w highNo

SqueezeOff

Bollinger width41.77%

%B0.91

Donchian pos92.98%

Donchian high33.50

Donchian low22.67

AVWAP (52w high)28.21

vs AVWAP high+16.06%

AVWAP (52w low)26.42

vs AVWAP low+23.90%

OBV trendUp

Chaikin MF (20)0.10

Today vs 20d0.63×

Avg vol (14d)319.9K

Avg vol (20d)324.08K

Avg $ vol (20d)8.72M

Market cap624.08M

RS Rating99 / 99

RS 3m (vs SPY)+38.27%

RS 6m (vs SPY)+5.20%

RS line new highNo

Trend template6/8

Technical rank91.7

1 week+8.70%

1 month+32.23%

3 months+35.35%

6 months+6.78%

1 year+168.36%

YTD+44.87%

P/E-2.58

P/B-1.86

P/S179.49

P/FCF-20.55

EPS-32.37

Div yield—

ROE72.11%

ROA-221.97%

Debt/Eq—

Current7.56

EV/EBITDA-12.60

Gross margin—

Net margin—

Rev growth-67.37%

EPS growth-280.76%

Price target53.00

Target upside61.88%

Analyst ratingBuy

Institutional106.93%

Ent. value523.73M

Revenue0

Net income-129.72M

Gross profit—

Free cash flow-30.37M

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out11.61M

Employees44

ListedThu, Aug 12, 2021

Free float4.11M

Float %47.9%

Short interest—

Days to cover—

Short volume28.1%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est−$4.75 vs −$1.32

Last surprise-259.9% miss

Setup gradeD

Conviction2 / 100

Pattern quality—

Tech rank91.7 / 100

Group rank23 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmTweezer top

Financials as of Wed, Sep 30, 2026 · quarterly.

SRZN technical analysis

Trend

SRZN's moving averages are mixed — no clean uptrend or downtrend. It closed 29.1% above the 50-day ($25.35) and 28.4% above the 200-day ($25.49). ADX(14) at 35 points to a strong, established trend. It meets 6 of 8 trend-template criteria.

Momentum

RSI(14) is 63, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.

Volume and volatility

Volume on the latest session ran 0.6× its 20-day average. It trades about $8.7M a day on average. ATR(14) is $2.45, 7.5% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.10) shows accumulation.

Key levels

The 52-week range is $11.66 to $37.83; price is 13.5% below the high and 180.8% above the low. The VWAP anchored at the 52-week high is $28.21, below price.

Performance

SRZN returned +8.7% (1 week), +32.2% (1 month), +35.4% (3 months), +6.8% (6 months), +168.4% (1 year), +44.9% (year to date).

About Surrozen, Inc.

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).

Biological Products, (No Diagnostic Substances) · Listed 2021 · 44 employees

Insider activity

SEC Form 4 transactions in SRZN · open-market 3 sells

Insider	Side	Shares	Value	Traded	Filed
Kutzkey Tim Director · Option (right to buy) · 2026-05-13	Grant	5.55K	$0	2026-05-13	2026-05-19
Haak-Frendscho Mary Director · Director Stock Option (right to buy) · 2026-05-13	Grant	5.55K	$0	2026-05-13	2026-05-14
Rothenberg Mace Director · Director Stock Option (right to buy) · 2026-05-13	Grant	5.55K	$0	2026-05-13	2026-05-14
Berkenblit Anna Director · Director Stock Option (right to buy) · 2026-05-13	Grant	5.55K	$0	2026-05-13	2026-05-14
CHAI CHRISTOPHER Y Director · Director Stock Option (right to buy) · 2026-05-13	Grant	5.55K	$0	2026-05-13	2026-05-14
WOODHOUSE DAVID J Director · Director Stock Option (right to buy) · 2026-05-13	Grant	5.55K	$0	2026-05-13	2026-05-14
BJERKHOLT ERIC Director · Director Stock Option (right to buy) · 2026-05-13	Grant	5.55K	$0	2026-05-13	2026-05-14
Williams Charles O Chief Operating Officer · Common Stock · 2026-05-04	Sell	2.04K	$68K	2026-05-04	2026-05-05
Parker Craig C Chief Executive Officer · Common Stock · 2026-05-04	Sell	4.52K	$151K	2026-05-04	2026-05-05
Li Yang Exec. Vice President, Research · Common Stock · 2026-05-04	Sell	1.58K	$53K	2026-05-04	2026-05-05

SEC filings

EDGAR filings in SRZN · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.